"A machine in the city that could see inside the body," was how Dr. Ruby Wang's grandmother first heard rumours of the technology that would eventually help mend her nine-year-old son's crooked arm, LinkedIn reported.
That personal history anchors a new book, China Cure: The Rise of a Biotech, AI Medicine and Global Health Superpower. The text charts an extraordinary evolution. It maps a journey from an era of barefoot doctor tree-branch splints to managing a volume of clinical trials surpassed only by the United States.
Decades of Bureaucratic Hurdles
Decades after that initial cart ride to Ningbo for an X-ray, Wang's maternal grandmother faced a rare gut cancer. The prescribed treatment was Gleevec.
Securing the medication was far from simple. It required a Novartis programme offering free drugs strictly for clinical trial participants.
A New Engine for Pharmaceutical Funding
Today, the mechanics of pharmaceutical research look starkly different.
A Chinese MSc student explained to observers a distinct financial rhythm. Domestic biotechs finance studies faster than Western counterparts.
They achieve this by selling molecules proven in Phase 1 trials directly to companies focusing on Phase 2 development. It is a strategy rarely utilized in Western markets.
China now runs more clinical trials each year than any country except the US.
Patient Integration in the United Kingdom
For UK patients, deployment follows a different path.
Systems operating across 9.1 million patient records match individuals directly with ongoing clinical trials visible in their medical files.
If a patient identifies a useful trial, they can share their records immediately with researchers to expedite enrollment.
